Navigation Links
Pharmasset Reports Fiscal First Quarter 2009 Financial Results
Date:2/9/2009

smith@pharmasset.com>richard.smith@pharmasset.com Office: +1 (609) 613-4181

Forward-Looking Statements

Pharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding our business that are not historical facts are "forward-looking statements" that involve risks and uncertainties, including without limitation,, the risk that adverse events could cause the cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product candidates, the risk that the results of previously conducted studies involving our product candidates will not be repeated or observed in ongoing or future studies involving our product candidates, the risk that our collaboration with Roche will not continue or will not be successful and the risk that any one or more of our product candidates will not be successfully developed and commercialized. For a discussion of these risks and uncertainties, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section of our Annual Report on Form 10-K for the fiscal year ended September 30, 2008 and our Quarterly Report on Form 10-Q for the period ended December 31, 2008 filed with the Securities and Exchange Commission entitled "Risk Factors" and discussions of potential risks and uncertainties in our subsequent filings with the Securities and Exchange Commission.

                            PHARMASSET, INC.
      CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE NET LOSS
                               (UNAUDITED)

                                               Three Months Ended
                                                  December 31,
                                                  ------------
                                               2008          2007
             
'/>"/>
SOURCE Pharmasset, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Pharmasset Announces $45.5 Million Registered Direct Offering of Common Stock
2. Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study With R7128 in Treatment Naive HCV Patients
3. Pharmasset to Present at Two Upcoming Investor Conferences
4. Pharmasset to Present at the Natixis Bleichroeder Hidden Gems Conference on Monday, October 13th
5. Pharmasset to Present at the JMP Securities Healthcare Focus Conference on Monday, October 6th
6. Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders
7. Pharmasset to Present at the Upcoming Citibank and Morgan Stanley Investor Conferences
8. Pharmasset to Present at the Canaccord Adams Global Growth Conference on Tuesday, August 12th
9. Pharmasset Announces $25.9 Million Registered Direct Offering of Common Stock
10. Pharmasset Joins Russell 3000 Index
11. Pharmasset to Present at the Needham & Co. Biotechnology and Medical Technology Conference on Wednesday, June 11th
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 2014 /CNW/ - Sunovion Pharmaceuticals Canada Inc. (Sunovion) today ... acetate) for use as a once-daily adjunctive therapy for ... who are not satisfactorily controlled with conventional therapy.  APTIOM ... under 18 years of age. Epilepsy ... according to Epilepsy Canada, it affects 0.6% of the ...
(Date:7/10/2014)... 2014 Deep Knowledge Ventures last ... on ‘Commercialising Longevity Research’ and welcomed a host ... London Bioscience Innovation Center for the event, organised ... Analytics Ltd. The meeting highlighted the need for ... for age-related disease, as well as the crucial ...
(Date:7/10/2014)... OMICS Group’s 5th International conference and ... 2014 at Double Tree by Hilton Beijing, China is ... Analytical & Bioanalytical research methods only to facilitate improved ... occasion, Dr. Srinubabu Gedela, MD of OMICS Group Inc ... remarkable one in bringing a unique and international mix ...
(Date:7/10/2014)... , July 10, 2014  Kainos Capital, a ... brands, today announced that it has acquired the Slim-Fast ... in the business. Terms of the transaction were not ... and meal replacement business that markets ready-to-drink shakes, powders, ... North America and in the ...
Breaking Biology Technology:Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 2DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 5DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 6A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4Kainos Capital Acquires Slim-Fast From Unilever 2
... recommend Corvalen(R) D-Ribose to boost cellular energy, NEW YORK, ... you,could sleep all year and not catch up? That,s how ... there was a good reason to be,exhausted -- five boys ... fix., Then came a sixth son, and she began ...
... System Combines Clinical Benefits of Dual Wavelengths Through ... Time While Providing a Uniform, Safe and Effective ... Treatment - New Offering Signals Company,s Expansion into International Laser ... Lipolysis Market, WESTFORD, Mass., April 28 Cynosure, ...
... Calif., April 28 Aida,Pharmaceuticals, Inc. (OTC Bulletin Board: ... its Phase 2 testing results of Rh-Apo2L and,expects to ... announced that the target cancers for the drug have ... targets,that the Company has chosen are ailments which Rh-Apo2L ...
Cached Biology Technology:D-Ribose Helps Energy-Starved Hearts 2Cynosure Introduces Smartlipo MPX(TM) Dual Wavelength Workstation for LaserBodySculpting(SM) 2Cynosure Introduces Smartlipo MPX(TM) Dual Wavelength Workstation for LaserBodySculpting(SM) 3Cynosure Introduces Smartlipo MPX(TM) Dual Wavelength Workstation for LaserBodySculpting(SM) 4Cynosure Introduces Smartlipo MPX(TM) Dual Wavelength Workstation for LaserBodySculpting(SM) 5Aida Pharmaceuticals, Inc. Announces Update on Progress of Rh-Apo2L Testing 2
(Date:7/11/2014)... OAK RIDGE, Tenn., July 11, 2014--Researchers at the ... received eight R&D 100 awards, presented by R&D ... innovations. , "These awards recognize the tremendous ... Energy Ernest Moniz. "Research and development at the ... its energy challenges and pursue the scientific and ...
(Date:7/11/2014)... near the City of Entiat on Tuesday, July 8, ... quickly grew to over 1,000 acres by evening. Three ... under investigation by the Washington Department of Natural Resources. ... resources in developing fire control strategies and tactics. Other ... Department of Natural Resources, (WA DNR), Bureau of Land ...
(Date:7/11/2014)... is creating a new professorship in tissue engineering ... for Molecular Engineering and the Marine Biological Laboratory, ... Millicent and Eugene Bell Foundation., The Eugene Bell ... Institute for Molecular Engineering. That endowed chair holder ... MBL,s Eugene Bell Center for Regenerative Biology and ...
Breaking Biology News(10 mins):ORNL wins eight R&D 100s 2ORNL wins eight R&D 100s 3ORNL wins eight R&D 100s 4New professorship in tissue engineering links molecular engineering, marine biology 2
... the atmosphere through summer thunderstorm clouds, according to a ... Letters . How much the warming effect of these ... not yet clear. To find out, researchers need to ... Pollution strengthens thunderstorm clouds, causing their anvil-shaped tops ...
... rate at which the rabies virus evolves in bats may ... to researchers at the University of Georgia, the U.S. Centers ... Belgium. Their study, published May 17 in the journal ... the most accurate predictor of the viral rate of evolution. ...
... physicists and University of Miami biologists addresses an ... do living cells figure out when and where ... Dimitrios Vavylonis and Associate Professor Fulvia Verde discovered ... a ballet of proteins that change its polarity. ...
Cached Biology News:Pollution teams with thunderclouds to warm atmosphere 2Pollution teams with thunderclouds to warm atmosphere 3Hitting snooze on the molecular clock: Rabies evolves slower in hibernating bats 2Hitting snooze on the molecular clock: Rabies evolves slower in hibernating bats 3A cell's first steps: Building a model to explain how cells grow 2
TMB Slow Kinetic One Component HRP Microwell Substrate, 1 L...
Request Info...
... Alkaline Phosphatase, Calf Intestinal (CIAP), catalyzes the ... and ribo- and deoxyribonucleoside triphosphates. This enzyme ... of linearized cloning vector DNA by removing ... also be used for the dephosphorylation of ...
100 adhesive strips....
Biology Products: